The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The FDA approved Johnson & Johnson's Spravato, a ketamine-based nasal spray, to treat adults with major depressive disorder ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Respondents who said they used other drugs recreationally were also likelier to say they used ketamine during the past year ...

The following is a summary of “Intranasal racemic ketamine maintenance therapy for patients with treatment-resistant ...

Dr. David Mahjoubi, a highly respected board-certified anesthesiologist and the founder of Ketamine Healing Clinic of Los Angeles and OC, has been recognized as a 2025 Top Patient Rated Doctor by Find ...

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

A multidisciplinary approach, including ketamine withdrawal and symptom management, is essential to mitigate long-term ...